However, established leukemia cells can be dependent on active translation for their maintenance (36), and AML subtypes, namely, those with RUNX1 mutations (37), are therapeutically sensitive to inhibition of protein synthesis. This evidence concerns the gene RUNX1 and acute myeloid leukemia.